<DOC>
	<DOCNO>NCT00970879</DOCNO>
	<brief_summary>The purpose study evaluate efficacy cotrimoxazole prophylaxis prevention malaria pregnancy HIV-infected woman , compare intermittent preventive treatment mefloquine .</brief_summary>
	<brief_title>Prevention Pregnancy-associated Malaria HIV-infected Women : Cotrimoxazole Prophylaxis Versus Mefloquine</brief_title>
	<detailed_description>Malaria infection pregnancy adverse effect mother fetus , include maternal anaemia low birth weight responsible mother infant mortality . It particular problem woman first second pregnancy woman HIV-positive . Maternal HIV infection potentiate many adverse effect . In HIV-infected woman , World Health Organization ( WHO ) advocate use insecticide-treated bednets , drug : If CD4 cell count 350/mm3 HIV disease WHO stage 2 , 3 4 , cotrimoxazole prophylaxis prevention pneumocystosis toxoplasmosis indicate , assume also protect woman malaria . Otherwise , receive least three dos intermittent preventive treatment ( IPT ) , commonly sulfadoxine-pyrimethamine ( SP ) give antenatal care visit . If IPT SP subject many investigation , cotrimoxazole efficacy never assess prevention malaria pregnancy . The investigator aim evaluate efficacy cotrimoxazole prophylaxis prevention malaria pregnancy HIV-infected woman . The investigator postulate cotrimoxazole prophylaxis inferior IPT woman , unrelated CD4 cell count . In control arm , investigator use mefloquine IPT . The safety efficacy drug already assess HIV-negative patient ( NCT00274235 ) . A randomized control trial conduct five hospital Benin . Pregnant woman enrol Antenatal Care unit Infectious Diseases unit set . All woman receive insecticide-treated bednets enrolment . Randomization stratify hospital CD4 cell count range . Women assign cotrimoxazole receive cotrimoxazole prophylaxis daily course pregnancy . Women assign mefloquine IPT receive mefloquine three time pregnancy . Women randomise arm low CD4 cell count advance HIV disease also receive cotrimoxazole prophylaxis prevention HIV/AIDS opportunistic infection . Drug efficacy judge prevalence placental malaria delivery . This study contribute updating recommendation concern prevention malaria pregnancy HIV-infected woman .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<criteria>Confirmed HIV seropositivity Permanent residency study catchment 's area Confirmed pregnancy , gestational age &lt; 28 week More 18 year age Karnofsky index â‰¥80 Willingness deliver hospital Written inform consent History allergy study drug : sulpha drug , mefloquine , quinine History presence major illness : severe renal disease , severe hepatic disease , severe neuropsychiatric disease Mefloquine halofantrine receive within 4 week prior enrolment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>malaria</keyword>
	<keyword>pregnancy</keyword>
	<keyword>HIV</keyword>
	<keyword>prevention</keyword>
	<keyword>cotrimoxazole</keyword>
	<keyword>mefloquine</keyword>
</DOC>